Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-8010 in Renal Impairment
NCT05812417Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of velufenacin in overactive bladder (OAB) (4 arms), sponsored by Dong-A ST. Primary endpoints: Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration at 48 hours and Peak Plasma Concentration at 48 hours. Started May 2023; status: completed.
02
Drugs
velufenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05812417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812417.